Karo Pharma to acquire Sylphar from Vendis Capital for $326m.

Karo Pharma, a company that provides a portfolio of everyday healthcare products and services that help prevent illness and treat health problems, agreed to acquire Sylphar, a Belgium-based company developing and marketing OTC products worldwide, from Vendis Capital, a private equity firm, for $326m. "Sylphar is highly complementary to Karo with an excellent fit to our strategy and vision. The acquisition brings fast growing consumer oriented brands and cutting edge team excelling in e-commerce and digital marketing. We are impressed by Sylphar's development, market positions and strong leadership team. The combination is a real win-win where we jointly will benefit from the strengths of the respective companies," Christoffer Lorenzen, Karo Pharma CEO.